Q BioMed (Q BioMed) YoY EBITDA Growth : 93.65% (As of Feb. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Q BioMed YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Q BioMed's YoY EBITDA Growth for the quarter that ended in Feb. 2023 was 93.65%.

Q BioMed's EBITDA per Share for the three months ended in Feb. 2023 was $-0.00.

Q BioMed YoY EBITDA Growth Historical Data

The historical data trend for Q BioMed's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q BioMed YoY EBITDA Growth Chart

Q BioMed Annual Data

Trend

Nov13

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

YoY EBITDA Growth

Get a 7-Day Free Trial

49.66

12.07

-1.72

51.60

95.12

Q BioMed Quarterly Data
	May18	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23
YoY EBITDA Growth	Get a 7-Day Free Trial															35.71	65.22	80.33	149.21	93.65

Q BioMed YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Q BioMed's YoY EBITDA Growth for the fiscal year that ended in Nov. 2022 is calculated as:

	YoY EBITDA Growth (A: Nov. 2022 )
=	(EBITDA per Share (A: Nov. 2022 )	-	EBITDA per Share (A: Nov. 2021 ))	/	\| EBITDA per Share (A: Nov. 2021 ) \|
=	(-0.014	-	-0.287)	/	\| -0.287 \|
=	95.12 %

Q BioMed's YoY EBITDA Growth for the quarter that ended in Feb. 2023 is calculated as:

	YoY EBITDA Growth (Q: Feb. 2023 )
=	(EBITDA per Share (Q: Feb. 2023 )	-	EBITDA per Share (Q: Feb. 2022 ))	/	\| EBITDA per Share (Q: Feb. 2022 )) \|
=	(-0.004	-	-0.063)	/	\| -0.063 \|
=	93.65 %

Q BioMed YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Q BioMed's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Q BioMed (Q BioMed) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q BioMed Inc (OTCPK:QBIO) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

N/A

Address

C/o Ortoli Rosenstadt LLP, 366 Madison Avenue, 3rd Floor, New York, NY, USA, 10017

Website

https://www.qbiomed.com

Q BioMed Inc is a biomedical acceleration and development company. It has a focus on licensing, acquiring, and providing strategic resources to life sciences and healthcare companies. The company intends to mitigate risk by acquiring multiple assets over time and across a broad spectrum of healthcare-related products, companies, and sectors. Generic Strontium Chloride Sr-89 Injection USP (Strontium-89) is a radioactive pharmaceutical injection to relieve bone pain in patients with painful skeletal metastases. It also has three development-stage products: QBM-001 for rare pediatric non-verbal autism spectrum disorder, Uttroside-B for liver cancer, and MAN 01 for glaucoma.

Executives

William S Rosenstadt	director, 10 percent owner, officer: Chief Legal Officer	ORTOLI ROSENSTADT LLP, 501 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022
Denis Corin	director, 10 percent owner, officer: Chief Executive Officer	10 MARKET STREET, SUITE 427, GRAND CAYMAN E9 KY1-9006
Rick Panicucci	director	501 MADISON STREET, 14TH FLOOR, NEW YORK NY 10022
Alan P Lindsay	10 percent owner	580 HORNBY STREET, FIFTH FLOOR, VANCOUVER BC CANADA V6C 2E7 A1